[Long-term therapy of immunologic diseases with special reference to the use of immunosuppressive agents].
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use; D009393:Nephritis / Q000188:drug therapy; D013921:Thrombocytopenia / Q000188:drug therapy; D013997:Time Factors
D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D000324:Adrenocorticotropic Hormone; D001379:Azathioprine; D008727:Methotrexate
Langzeitbehandlung von Immunopathien unter besonderer Berücksichtigung immunsuppressiver Medikamente.